Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Leerink Swann issued their Q3 2017 earnings per share estimates for Intra-Cellular Therapies in a note issued to investors on Tuesday. Leerink Swann analyst P. Matteis anticipates that the biopharmaceutical company will post earnings per share of ($0.48) for the quarter. Leerink Swann currently has a “Market Perform” rating and a $12.00 target price on the stock. Leerink Swann also issued estimates for Intra-Cellular Therapies’ Q4 2017 earnings at ($0.55) EPS, FY2017 earnings at ($2.06) EPS, FY2018 earnings at ($2.44) EPS and FY2019 earnings at ($2.57) EPS.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.03 million. During the same quarter in the previous year, the company posted ($0.71) earnings per share. The company’s revenue for the quarter was down 52.2% compared to the same quarter last year.
WARNING: “Q3 2017 Earnings Forecast for Intra-Cellular Therapies Inc. Issued By Leerink Swann (ITCI)” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://stocknewstimes.com/2017/08/19/q3-2017-earnings-forecast-for-intra-cellular-therapies-inc-issued-by-leerink-swann-itci.html.
Several other analysts have also recently commented on ITCI. Piper Jaffray Companies set a $10.00 target price on Intra-Cellular Therapies and gave the stock a “hold” rating in a report on Thursday, August 10th. ValuEngine upgraded Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a report on Friday. BidaskClub cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $24.43.
Intra-Cellular Therapies (NASDAQ ITCI) opened at 11.11 on Thursday. The firm’s market cap is $482.44 million. The stock’s 50 day moving average is $11.81 and its 200 day moving average is $12.48. Intra-Cellular Therapies has a one year low of $7.85 and a one year high of $45.20.
A number of large investors have recently made changes to their positions in ITCI. Wasatch Advisors Inc. raised its stake in shares of Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after buying an additional 654,400 shares in the last quarter. Clough Capital Partners L P increased its position in Intra-Cellular Therapies by 157.0% in the first quarter. Clough Capital Partners L P now owns 898,750 shares of the biopharmaceutical company’s stock worth $14,605,000 after buying an additional 549,100 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Intra-Cellular Therapies by 419.3% in the second quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after buying an additional 522,565 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Intra-Cellular Therapies by 336.1% in the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after buying an additional 447,586 shares in the last quarter. Finally, BB Biotech AG increased its position in Intra-Cellular Therapies by 22.2% in the first quarter. BB Biotech AG now owns 1,925,000 shares of the biopharmaceutical company’s stock worth $31,281,000 after buying an additional 350,000 shares in the last quarter. 66.66% of the stock is currently owned by institutional investors and hedge funds.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
